MAM
CNCE

Martingale Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Martingale Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-71,815
Closed -$706K – 1077
2020
Q3 		$706K Buy
71,815
+9,901
+16% +$97.6K 0.01% 723
2020
Q2 		$617K Buy
+61,914
New +$594K 0.01% 840

Other funds holding CNCE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LC
L1 Capital Melbourne VIC 3000, Australia $2.55B AUM 80.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Martingale Asset Management's CNCE Position: Q4 2020 in Review

Martingale Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2020, closing a stake of 71,815 shares — an estimated $706K sold.

Martingale Asset Management first reported a position in CNCE in Q2 2020 and held it in 2 quarters. The position peaked at $706K in Q3 2020. 100 funds tracked by Wall St. Rank hold CNCE as of Q4 2020.

  • Martingale Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Martingale Asset Management sold 71,815 Concert Pharmaceuticals, Inc. shares in Q4 2020, an estimated $706K.
  • Martingale Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • Martingale Asset Management's Concert Pharmaceuticals, Inc. position peaked at $706K in Q3 2020.
  • 100 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2020.

Based on Martingale Asset Management's 13F filing for Q4 2020, filed 10 Feb 2021.